These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 5668416)

  • 1. [A contribution to the biochemical treatment of the akinetic type of the Parkinson's syndrome].
    Völler GW
    Med Welt; 1968 Feb; 5():338-41. PubMed ID: 5668416
    [No Abstract]   [Full Text] [Related]  

  • 2. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease; modern treatment.
    Tolosa E
    Minn Med; 1973 Jun; 56(6):497-502. PubMed ID: 4575903
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug therapy of parkinsonism.
    Yahr MD; Duvoisin RC
    N Engl J Med; 1972 Jul; 287(1):20-4. PubMed ID: 4555145
    [No Abstract]   [Full Text] [Related]  

  • 5. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa].
    Gerstenbrand F; Prosenz P
    Praxis; 1965 Nov; 54(46):1373-7. PubMed ID: 5899418
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 7. [On disturbances in space perception caused by Parkinson's syndrome].
    Metzel E
    Dtsch Med Wochenschr; 1965 Oct; 90(44):1955-7. PubMed ID: 5833101
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical remarks on the action of intravenous and oral levo-dopa in the treatment of Parkinson's disease (135 cases)].
    Fasano VA; Urciuoli R; Broggi G; Cannella M; Lombard GF
    Neurochirurgie; 1970; 16(2):171-8. PubMed ID: 5451127
    [No Abstract]   [Full Text] [Related]  

  • 9. [The trial of intravenous L-DOPA in patients with Parkinson's disease].
    Nardini M; Fieschi C; Agnoli A; Arcioli I; Zanette E
    Riv Neurol; 1970; 40(2):75-85. PubMed ID: 5429003
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
    Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of a substance of the amphetamine group in Parkinson's syndrome with prevalent akinesia. Clinical experiences and controls of action of cyclohexyl-isopropyl-methylamine HCl].
    Umbach W; Woywode J
    Med Welt; 1965 Oct; 41():2329-36. PubMed ID: 5865786
    [No Abstract]   [Full Text] [Related]  

  • 13. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Degkwitz R
    Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
    [No Abstract]   [Full Text] [Related]  

  • 14. [Parkinson's disease: current therapeutic aspects].
    Casati C
    Clin Ter; 1971 Jan; 56(1):71-9. PubMed ID: 4944741
    [No Abstract]   [Full Text] [Related]  

  • 15. "Rational hope" in the early treatment of Parkinson's disease.
    Sourkes TL
    Can J Physiol Pharmacol; 1999 Jun; 77(6):375-82. PubMed ID: 10537223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using monoamine oxidase type B inhibitors in Parkinson's disease.
    Ben-Shlomo Y; Bhatia K
    BMJ; 2004 Sep; 329(7466):581-2. PubMed ID: 15361418
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of parkinsonism using L-dopa. I].
    Glass J
    Z Arztl Fortbild (Jena); 1972 Dec; 66(23):1195-9. PubMed ID: 4652156
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.